Thursday, October 22, 2026 Published by AdvancedCare USA Inc.

TheraNews
Subscribe

Archive summary Clinical & research

Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)

RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)--Apr 21, 2026--

Summary of reporting by rutlandherald 1 min read Markdown

Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)

Originally reported by rutlandherald. Read more

Source: https://www.rutlandherald.com/news/business/merck-and-eisai-provide-update-on-phase-3-litespark-012-trial-evaluating-first-line-combination/article_96229ead-e9d2-5749-beb3-16a5a1fe1a0f.html

Newsletter

The weekly digest

Weekly digest of US behavioral health policy and regulation, source-linked and practitioner-edited. Free; unsubscribe in one click.